The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules
Interacts with KNDC1 (via KIND2); the interaction enhances MAP2 phosphorylation and localizes KNDC1 to dendrites. Interacts with DPYSL5 (PubMed:33894126)
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to GIMAP2, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 8
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT01818921 | Obesity, Over-weight, Prader-Willi Syndrome | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome | PHASE2 | COMPLETED |
| NCT01316471 | Chronic Pain, Abdominal Pain, Headache | Internet Intervention for Adolescents With Chronic Pain | PHASE2 | COMPLETED |
| NCT01666691 | Obesity | An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects | PHASE2 | COMPLETED |
| NCT00174109 | Oral Cancer | The Relation of Microtubule-Associated Protein 2 and Cell Migration | N/A | UNKNOWN |
| NCT07482475 | COPD (Chronic Obstructive Pulmonary Disease), Cancer Lung Screening, Smoking Cigarette | University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2 | N/A | RECRUITING |
| NCT03138538 | Advanced Solid Tumors, Metastatic Renal Cell Carcinoma | M8891 First in Human in Solid Tumors | PHASE1 | TERMINATED |
| NCT02063295 | Obesity, Over-weight, Hypothalamic Injury, Craniopharyngioma | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury | PHASE2 | COMPLETED |
| NCT01372761 | Obesity | Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers | PHASE1 | COMPLETED |
| NCT01507077 | Obesity | ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity | PHASE1 | COMPLETED |
| NCT03254368 | Type 2 Diabetes Mellitus, Overweight and Obesity | Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes | PHASE2 | COMPLETED |